RecruitingNCT07239583
Genotype and Disease Burden of RSV in Older Vietnamese Adults (RSV: Respiratory Syncytial Virus )
A Description of the Proportion, Genotype Distribution of Respiratory Syncytial Virus and the Severity of Disease in Hospitalized Elderly in Vietnam
Sponsor
Tam Anh Research Institute
Enrollment
1,000 participants
Start Date
Oct 6, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This observational, prospective, multicenter study aims to estimate the proportion of RSV infection in adults aged 60 years and older hospitalized due to acute respiratory infections or exacerbation of cardiopulmonary disease.
Eligibility
Min Age: 60 Years
Inclusion Criteria6
- Individuals ≥ 60 years old at the time of screening (calculated from the date of birth to the date of screening)
- ARI or exacerbation of cardiopulmonary diseases diagnosed at the time of admission. ARI or ARI-compatible symptoms were defined as either:
- New onset or increase from baseline of: nasal congestion, rhinorrhea, sore throat, hoarseness, cough, sputum production, dyspnea, wheezing, hypoxemia, or
- Admitting diagnosis suggestive of ARI (e.g., pneumonia, upper respiratory infection, bronchitis, influenza, cough, viral respiratory illness, respiratory distress, or respiratory failure), or
- Admitting diagnosis was the exacerbation of an underlying cardiac or pulmonary disease involving acute respiratory symptoms within the previous 2 weeks (e.g., congestive heart failure \[CHF\], chronic obstructive pulmonary disease \[COPD\], or asthma exacerbation).
- The participant agrees to voluntarily participate in this study.
Exclusion Criteria4
- Symptom onset \> 6 days prior to screening date
- Acute symptoms confirmed to be unrelated to infection or as assessed by the investigator
- Admission to any hospital within the 30 days preceding the screening date
- Previously enrolled in the study in the last 45 days
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07239583
Related Trials
A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease
NCT0721457164 locations
A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children
NCT074025124 locations
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease
NCT072201099 locations
A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant
NCT0709286537 locations
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
NCT068178893 locations